Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

About WAPE
U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Perspective Therapeutics Presents Interim Phase 1/2a Monotherapy Data for VMT01 in Advanced Melanoma | WAPE

Back All news

Newsfiscal.ai

Perspective Therapeutics Presents Interim Phase 1/2a Monotherapy Data for VMT01 in Advanced Melanoma

Nov 7, 2026, 09:03 ET · Published

View source

Article summary

Perspective Therapeutics reported positive interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) at the SITC 2026 Annual Meeting.

An excerpt from the original article.

Related companies

Perspective Therapeutics, Inc. Common StockCATXView stock

Perspective Therapeutics Presents Interim Phase 1/2a Monotherapy Data for VMT01 in Advanced Melanoma

Article summary

Related companies

Analyzed by WAPE AI.

Comments —